Our study highlights critical insights into the molecular alterations within the placenta associated with GDM, focusing on pyruvate kinase M2 (PKM2), AMP-activated protein kinase (AMPK), and the mechanistic target of rapamycin (mTOR) pathway. The gene discussed is PKM; the disease is gestational diabetes.